Malar J

A field bioassay for assessing ivermectin bio-efficacy in wild malaria vectors.Ominde KM, Kamau Y, Karisa J, Muturi MN, Kiuru C, Wanjiku C, Babu L, Yaah F, Tuwei M, Musani H, Ondieki Z, Muriu S, Mwangangi J, Chaccour C, Maia MF
Malar J, (2023). 22:291

Malaria vaccine coverage estimation using age-eligible populations and service user denominators in Kenya.Moturi AK, Jalang'o R, Cherono A, Muchiri SK, Snow RW, Okiro EA
Malar J, (2023). 22:287

Border malaria: defining the problem to address the challenge of malaria elimination.Li X, Snow RW, Lindblade K, Noor AM, Steketee R, Rabinovich R, Gopinath D, Gasimov E, Alonso PL
Malar J, (2023). 22:239

Determinants of utilization of malaria preventive measures during pregnancy among women aged 15 to 49 years in Kenya: an analysis of the Malaria Indicator Survey 2020.Mkubwa B, Kagura J, Chirwa T, Ibisomi L, Kinyanjui S
Malar J, (2022). 21:398

The use of routine health facility data for micro-stratification of malaria risk in mainland Tanzania.Thawer SG, Golumbeanu M, Munisi K, Aaron S, Chacky F, Lazaro S, Mohamed A, Kisoka N, Lengeler C, Molteni F, Ross A, Snow RW, Pothin E
Malar J, (2022). 21:345

Challenges with adherence to the 'test, treat, and track' malaria case management guideline among prescribers in Ghana.Kolekang AS, Afrane Y, Apanga S, Zurovac D, Kwarteng A, Afari-Asiedu S, Asante KP, Danso-Appiah A
Malar J, (2022). 21:332

Malaria attributable fractions with changing transmission intensity: Bayesian latent class vs logistic models.Mwai K, Nkumama I, Thairu A, Mburu J, Odera D, Kimathi R, Nyamako L, Tuju J, Kinyanjui S, Musenge E, Osier F
Malar J, (2022). 21:326

House screening for malaria control: views and experiences of participants in the RooPfs trial.Jones C, Matta A, Pinder M, D'Alessandro U, Knudsen J, Lindsay SW
Malar J, (2022). 21:294

Maintenance of high temporal Plasmodium falciparum genetic diversity and complexity of infection in asymptomatic and symptomatic infections in Kilifi, Kenya from 2007 to 2018.Kimenyi KM, Wamae K, Ngoi JM, de Laurent ZR, Ndwiga L, Osoti V, Obiero G, Abdi AI, Bejon P, Ochola-Oyier LI
Malar J, (2022). 21:192

Sub-national tailoring of malaria interventions in Mainland Tanzania: simulation of the impact of strata-specific intervention combinations using modelling.Runge M, Thawer SG, Molteni F, Chacky F, Mkude S, Mandike R, Snow RW, Lengeler C, Mohamed A, Pothin E
Malar J, (2022). 21:92

Resurgent and delayed malaria.Greenwood B, Zongo I, Dicko A, Chandramohan D, Snow RW, Ockenhouse C
Malar J, (2022). 21:77

Factors influencing health workers' compliance with outpatient malaria 'test and treat' guidelines during the plateauing performance phase in Kenya, 2014-2016.Amboko B, Stepniewska K, Machini B, Bejon P, Snow RW, Zurovac D
Malar J, (2022). 21:68

Adherence to malaria management guidelines by health care workers in the Busoga sub-region, eastern Uganda.Mpimbaza A, Babikako H, Rutazanna D, Karamagi C, Ndeezi G, Katahoire A, Opigo J, Snow RW, Kalyango JN
Malar J, (2022). 21:25

Maplaria: a user friendly web-application for spatio-temporal malaria prevalence mapping.Giorgi E, Macharia PM, Woodmansey J, Snow RW, Rowlingson B
Malar J, (2021). 20:471

Identifying prognostic factors of severe metabolic acidosis and uraemia in African children with severe falciparum malaria: a secondary analysis of a randomized trial.Mzumara G, Leopold S, Marsh K, Dondorp A, Ohuma EO, Mukaka M
Malar J, (2021). 20:282

The Plasmodium falciparum Rh5 invasion protein complex reveals an excess of rare variant mutations.Ndwiga L, Osoti V, Ochwedo KO, Wamae K, Bejon P, Rayner JC, Githinji G, Ochola-Oyier LI
Malar J, (2021). 20:278

Determinants of the varied profiles of Plasmodium falciparum infections among infants living in Kintampo, Ghana.Botwe AK, Oppong FB, Gyaase S, Owusu-Agyei S, Asghar M, Asante KP, Farnert A, Osier F
Malar J, (2021). 20:240

Spatial-temporal clustering of malaria using routinely collected health facility data on the Kenyan Coast.Kamau A, Mtanje G, Mataza C, Bejon P, Snow RW
Malar J, (2021). 20:227

Malaria micro-stratification using routine surveillance data in Western Kenya.Alegana VA, Suiyanka L, Macharia PM, Ikahu-Muchangi G, Snow RW
Malar J, (2021). 20:22

Building momentum for malaria vaccine research and development: key considerations.Chitnis CE, Schellenberg D, Vekemans J, Asturias EJ, Bejon P, Collins KA, Crabb BS, Herrera S, Laufer M, Rabinovich NR, Roestenberg M, Shearley A, Tinto H, Wentworth M, O'Brien K, Alonso P
Malar J, (2020). 19:421